Best Pemazyre (Pemagatinib) Medicine in India

Pemazyre (Pemigatinib) is a targeted anticancer medicine used to treat certain adults with advanced or metastatic cholangiocarcinoma (bile duct cancer) whose tumors have a specific FGFR2 fusion or rearrangement and have progressed after at least one prior systemic treatment. It may also be used to treat certain adults with myeloid or lymphoid neoplasms with an FGFR1 rearrangement. Pemigatinib works by blocking abnormal FGFR signaling involved in cancer cell growth and survival, helping to slow the progression of the disease.

Pemazyre (Pemigatinib) should be taken exactly as prescribed by your doctor. It is usually taken once daily according to a specific treatment schedule and may be taken with or without food. Swallow the tablet whole with water and do not crush, chew, or break it. Regular eye examinations and blood tests may be required during treatment to monitor your eyes, phosphate levels, liver function, kidney function, and overall response to therapy.

Common side effects of Pemazyre may include high phosphate levels, hair loss, diarrhea, dry mouth, fatigue, changes in taste, nausea, constipation, dry skin, and mouth sores. Pemigatinib may also cause serious eye problems and changes in phosphate levels. Inform your doctor promptly if you experience blurred or changed vision, eye pain, severe weakness, muscle cramps, confusion, or other unusual symptoms. Before starting treatment, tell your doctor about all medical conditions and medicines, vitamins, herbal products, and supplements you are taking.

Treatment of FGFR2-Altered Bile Duct Cancer

Pemazyre (Pemigatinib) is used to treat certain adults with advanced or metastatic cholangiocarcinoma (bile duct cancer) whose tumors have an FGFR2 fusion or rearrangement and have progressed after previous systemic treatment. It works by blocking abnormal FGFR signaling, which helps control cancer cell growth and survival, thereby helping to slow tumor growth and disease progression. Pemigatinib may also be used for certain FGFR1-rearranged myeloid or lymphoid neoplasms, helping control the abnormal growth of affected blood cells.

Some side effects of Pemazyre (Pemigatinib) may improve as the body adjusts to the medicine. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Pemazyre (Pemagatinib)

Take Pemazyre (Pemigatinib) exactly as prescribed by your doctor. It is usually taken once daily according to the recommended treatment schedule and may be taken with or without food. Swallow the tablet whole with water and do not crush, chew, or break it. Take it at approximately the same time each day. If you miss a dose, follow your doctor's instructions rather than taking an extra dose to make up for it. Continue treatment for as long as recommended by your healthcare professional.

Pemazyre contains Pemigatinib, a targeted medicine that blocks fibroblast growth factor receptors (FGFRs), particularly FGFR1, FGFR2, and FGFR3. These receptors can send signals that promote abnormal cancer cell growth and survival. By inhibiting FGFR signaling, Pemigatinib helps slow the growth and spread of cancer cells in tumors with specific FGFR abnormalities.

• Maintain the medicine at a controlled room temperature of 20°C to 25°C.
• Keep it in a dry area away from excessive heat and humidity.
• Leave the product in its original packaging until it is needed.
• Store the medicine securely where children cannot reach it.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Pemazyre (Pemigatinib).

Pregnancy CONSULT YOUR DOCTOR

Pemazyre may cause serious harm to an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant. Use effective contraception during treatment as advised by your doctor.

Breastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment with Pemazyre. Consult your doctor for guidance on when breastfeeding can be safely resumed.

Driving CONSULT YOUR DOCTOR

Pemazyre may cause fatigue, dizziness, or vision changes that can affect your ability to drive safely. Avoid driving if your vision or alertness is affected.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment. Dose adjustments or additional monitoring may be required.

Liver CAUTION

Tell your doctor if you have liver problems. Pemazyre may require additional monitoring or dose adjustment in patients with liver impairment.

• Take Pemazyre exactly as prescribed by your doctor and follow the recommended treatment schedule.
• Swallow the tablet whole with water. Do not crush, chew, or break it.
• Take your doses at approximately the same time each day, with or without food.
• Attend regular blood tests and eye examinations as recommended by your doctor.
• Inform your doctor promptly about vision changes, severe weakness, muscle cramps, or any unusual or worsening side effects.
• Read More About - Pemazyre (Pemagatinib) from Pharma Five.

Pharma Five, can assist patients in arranging the import of Pemazyre (Pemigatinib) in small quantities for personal use. For this purpose, the applicant is required to submit an application in Form 12A along with a prescription provided by a Registered Medical Practitioner (RMP).

Pharma Five assists patients requiring Pemazyre (Pemigatinib) through professional pharmaceutical facilitation services, helping them access this and other specialized medicines through the relevant import process. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.